Avalo Therapeutics Inc Sustainability Reports
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of targeted therapeutics for patients with significant unmet medical need in immunology and rare genetic diseases. Their lead product asset is an anti-IL-1B monoclonal antibody targeting inflammatory diseases.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300GPK6FPJ3X8SZ39
FIGI: BBG001V1GPQ9
3 reports from 2019 to 2024
